Latest news with #EtonCaresProgram
Yahoo
29-05-2025
- Business
- Yahoo
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution available in the United States, marking a major milestone for pediatric care. Designed for children aged five and older with adrenocortical insufficiency, a rare disorder where the adrenal glands do not produce enough cortisol, KHINDIVI offers a 1mg/ml ready-to-use liquid formulation. This eliminates the need for splitting or crushing tablets and allows for precise, incremental dosing tailored to each child's needs. The solution does not require refrigeration, mixing, or shaking, making it especially suitable for patients who have trouble swallowing pills or need administration via a gastric tube. A clinical researcher in a lab examining a new biopharmaceutical product. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) expects to launch KHINDIVI commercially the week of June 2, with combined peak sales from KHINDIVI and its companion product, ALKINDI SPRINKLE, projected to exceed $50 million annually. The medication will be distributed exclusively through Anovo, a specialty pharmacy, and supported by the Eton Cares Program, which provides prescription fulfillment, insurance support, educational resources, and co-pay assistance. This FDA approval is seen as a significant advancement for families and clinicians managing pediatric adrenal insufficiency, offering a new, accurate, and accessible treatment option. While we acknowledge the potential of ETON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ETON and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
29-05-2025
- Business
- Business Insider
Eton Pharmaceuticals announces FDA approval for KHINDIVI
Eton Pharmaceuticals (ETON) 'announced the U.S. Food and Drug Administration approval of a New Drug Application for KHINDIVI Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml strength designed to eliminate the need to split or crush tablets, and to offer simple and accurate dosing specifically tailored to each patient's needs. It does not require refrigeration, mixing, or shaking – it is a ready-to-use oral liquid solution. KHINDIVI is designed to offer administration simplicity and dosing accuracy, and to provide a therapy option for patients who have difficulty swallowing tablets or with special administration needs, such as patients with a gastric tube. Adrenocortical insufficiency is a rare, but serious condition in which the adrenal glands do not produce sufficient cortisol. Eton estimates that there are more than 5,000 adrenal insufficiency patients in the U.S. between the ages of 5 and 17, and expects peak sales of KHINDIVI, combined with ALKINDI SPRINKLE, will exceed $50 million per year. KHINDIVI will be available in the coming days in the United States exclusively through Anovo, a specialty pharmacy dedicated to serving patients with rare and chronic conditions. Anovo will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance to allow for $0 co-pays for qualifying patients.' Confident Investing Starts Here:
